Wednesday, July 8, 2026

biotech · Coronary Artery Disease · Bronchopulmonary Dysplasia · ASBP

Aspire Biopharma Holdings

Aspire Biopharma Holdings clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Humacao, USA HQ
2019 Founded
Public company Type
ASBP · NYSE Ticker
Company details
Status
Public
HQ
Humacao, USA
Founded
2019
Programs
8
Drugs
8
Patents
1
Intelligence · Clinical Programs

Aspire Biopharma Holdings projects

4 ClinicalTrials.gov programs sponsored by Aspire Biopharma Holdings.

Aspire Biopharma Holdings has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. AdreView

    Aspire Biopharma Holdings

    Heart Failure

    approved small molecule completed

    1 trial
  2. Myocardial perfusion imaging

    Aspire Biopharma Holdings

    Coronary Artery Disease

    approved other completed

    1 trial
  3. Pulse Sequence

    Aspire Biopharma Holdings

    Atrial Fibrillation

    approved other completed

    1 trial
  4. Regadenoson

    Aspire Biopharma Holdings

    Coronary Artery Disease

    approved small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Aspire Biopharma Holdings have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.